STILLWATER, Okla., May 05, 2025 (GLOBE NEWSWIRE) -- USA Rare Earth, Inc. (Nasdaq: USAR) (USAR or the Company), today announced the closing of its previously announced private investment in public equity (PIPE) financing. The PIPE is with a single institutional investor for total gross proceeds of $75 million. The Company intends to use the proceeds from the offering to fund capital expenditures for its magnet manufacturing facility in Stillwater, Oklahoma, as well as for working capital and operating expens ...

Core Viewpoint - Inventiva has successfully completed the enrollment of the Phase 3 NATiV3 study for lanifibranor in MASH and has initiated the second tranche of its structured financing, raising €115.6 million in gross proceeds to support the drug's development [1][2][4]. Financing Details - The second tranche of structured financing amounts to €115.6 million gross (net proceeds of €108.5 million) [1][4]. - The financing was led by existing investors from the first tranche, including New Enterprise Associates, BVF Partners LP, and Samsara BioCapital [3]. Use of Proceeds - The net proceeds from the T2 Transaction will primarily be used to finance the development of lanifibranor in MASH, particularly the continuation of the NATiV3 Phase 3 clinical trial [4]. Financial Position - As of December 31, 2024, the company's cash and cash equivalents were €96.6 million, which was projected to cover operational needs until mid-Q3 2025 [5]. - Following the T2 Transaction, the company estimates sufficient net working capital to meet obligations for the next 12 months, extending financing capabilities until the end of Q3 2026 [6]. Future Funding Needs - The company will require additional funding to achieve long-term objectives for lanifibranor's development and potential commercialization through public offerings, private placements, or strategic partnerships [7]. Transaction Characteristics - The T2 Transaction involves the issuance of 42,488,883 new shares at a subscription price of €1.35 per share, with attached warrants [9][12]. - The Board confirmed that all conditions for the issuance of the second tranche have been satisfied, including the completion of enrollment in the NATiV3 study [10][11]. Shareholder Impact - The issuance of new shares and warrants will dilute existing shareholders, with significant changes in ownership percentages expected post-transaction [23][25][29].

Not for distribution to United States newswire services or for dissemination in the United States. TORONTO, May 01, 2025 (GLOBE NEWSWIRE) -- Volatus Aerospace Inc. (TSXV:FLT) (OTCQX:TAKOF) (Frankfurt: ABB) (“Volatus” or the “Company”) is pleased to announce that it has closed its previously announced upsized and fully subscribed non-brokered listed issuer financing exemption (LIFE) private placement (the "LIFE Offering"). The Company issued 25,000,000 units of the Company ("Units") at a price of $0.12 per U ...

Sokoman Minerals Corp. Files for Conditional Approval, Closes First Tranche of Non-Brokered Flow-Through Private-Placement FinancingMay 01, 2025 4:36 PM EDT | Source: Sokoman Minerals Corp.St. John's, Newfoundland and Labrador--(Newsfile Corp. - May 1, 2025) - Sokoman Minerals Corp. (TSXV: SIC) (OTCQB: SICNF) ("Sokoman" or the "Company") is pleased to announce that, further to its April 25, 2025, news release, the Company has filed documents with the TSX Venture Exchange (the "Exchange") seeki ...

PHILADELPHIA, May 1, 2025 /PRNewswire/ -- Doral Renewables LLC ("Doral") has successfully closed a $100 million corporate Letter of Credit facility. The Letters of Credit are expected to primarily be used for new interconnection and power purchase agreement obligations incurred during development of the Company's projects. This new facility is additive to the $185 million of existing corporate Letter of Credit capacity which Doral maintains. HSBC acted as Sole Arranger and Issuing Bank for this new facility ...

Medical Properties Trust (MPW) Q1 2025 Earnings Call May 01, 2025 11:00 AM ET Company Participants Charles Lambert - Senior Vice President, Finance and TreasurerEdward Aldag - Chairman, President & Chief Executive OfficerRosa Hooper - Senior VP of Operations & SecretaryKevin Hanna - SVP, Controller & CAOSteven Hamner - EVP and CFOMichael Carroll - Managing Director & Head of US Real Estate ResearchGeorgi Dinkov - Senior Equity Research AssociateOmotayo Okusanya - Managing Director Conference Call Participan ...

Financial Data and Key Metrics Changes - Genworth reported net income of $54 million or $0.13 per share for Q1 2025, with adjusted operating income of $51 million [9][24] - The liquidity position remains strong, ending the quarter with cash and liquid assets of $211 million [10][36] - The total estimated pretax statutory loss for U.S. Life insurance companies was $1 million, primarily driven by losses in life and annuities [9][32] Business Line Data and Key Metrics Changes - Enact contributed $137 million in adjusted operating income, reflecting strong performance and reserve releases [9][28] - The long-term care insurance segment reported an adjusted operating loss of $30 million, impacted by lower limited partnership income and anticipated premium declines [25] - Life and Annuities reported an adjusted operating loss of $33 million, with life insurance losses of $34 million due to seasonally high mortality [27][32] Market Data and Key Metrics Changes - CareScout achieved a significant increase in matches between policyholders and providers, growing from 52 matches in Q1 2024 to 576 in Q1 2025, representing over a 10x increase year over year [13] - The CareScout quality network now includes nearly 550 providers, achieving 90% coverage for the aged 65 census population in the U.S. [14][15] Company Strategy and Development Direction - The company continues to focus on three strategic priorities: increasing shareholder value, maintaining self-sustainability of legacy businesses, and expanding CareScout services [10][12] - Genworth is committed to managing U.S. life insurance companies as a closed system, leveraging existing reserves and capital to cover future claims without additional capital injections [31] - The company is developing a hybrid long-term care product and expanding its CareScout network to include assisted living communities [16][15] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in navigating potential macroeconomic challenges, including tariff negotiations and possible recession scenarios, while emphasizing the growing demand for aging care products [20][21] - The company anticipates continued strong growth in CareScout and expects to return similar levels of capital to shareholders in 2025 as in 2024 [29][38] Other Important Information - The company is actively engaged with policymakers regarding the WISH Act, which aims to provide financial support for long-term care [17][66] - Genworth has agreed to cover up to £80 million of AXA's losses in ongoing litigation, aligning interests for maximum recovery [41][42] Q&A Session Summary Question: Clarification on AXA litigation agreement - Management clarified that the agreement with AXA ensures alignment of interests for maximum recovery, with AXA claiming damages of approximately $700 million [41][42] Question: Future capital contributions for CareScout - Management indicated that while significant upfront capital is required for the new insurance entity, future contributions are expected to be manageable, potentially in the range of $20 million to $25 million over time [44][48] Question: Breakeven timeline for CareScout quality network - Management noted that while CareScout is not yet at breakeven, the projected savings from the network could significantly impact Genworth's claim costs, adding value to the company [50][54] Question: Tailwinds from the WISH Act for CareScout - Management discussed how the WISH Act could provide a framework for catastrophic coverage, aligning well with CareScout's offerings and addressing the long-term care financing gap [58][66]

Walker & Dunlop (WD) Q1 2025 Earnings Call May 01, 2025 08:30 AM ET Company Participants Kelsey Duffey - Senior Vice President-Investor RelationsWilly Walker - Chairman and CEOGreg Florkowski - Executive VP & CFOJade Rahmani - Managing DirectorSteve Delaney - Director of Mortgage Operator Day, and welcome to the Q1 twenty twenty five Walker and Dunlop, Inc. Earnings Call. Today's conference is being recorded. At this time, I'd like to turn the conference over to Kelsey Duffy. Please go ahead. Kelsey Duffey ...

Financial Data and Key Metrics Changes - The company reported GAAP diluted EPS of $1.25 and non-GAAP diluted EPS of $1.22 for Q1 2025, compared to $1.06 in Q1 2024, reflecting a significant increase in earnings driven by rate recovery and colder weather [6][9][10] - The company affirmed its long-term rate base and earnings per share growth rate targets of 4% to 6% [6][19] Business Line Data and Key Metrics Changes - The Electric and Gas segments contributed strongly to the earnings, with margin improvements driven by new rates and favorable weather conditions [9][10] - New rates contributed $0.20 to margin improvement, while favorable loads added $0.13, resulting in a total margin increase [10][11] Market Data and Key Metrics Changes - The Montana rate review is nearing completion, with a full natural gas settlement and a partial electric settlement reached [7][14] - The average bill impact from the gas case is approximately 9%, maintaining rates below the national average [18] Company Strategy and Development Direction - The company is focusing on opportunities with data centers and new large load opportunities, potentially achieving greater than 6% EPS growth [8] - The company is committed to maintaining a 5% dividend yield and a total growth profile of 9% to 11% over the next five years [8][19] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in delivering on earnings and rate-based growth commitments over the long term, despite not providing specific 2025 earnings guidance until the conclusion of the Montana rate review [19][20] - The company expects a lower contribution to overall earnings in Q2 2025 due to the timing of rate implementations [20] Other Important Information - The Montana legislature has passed wildfire and other constructive bills, which are pending the governor's approval, providing significant legal protections for the company [22][24] - The company has successfully priced $500 million of long-term debt to address its financing needs for 2025 [13][14] Q&A Session Summary Question: On the tariff proceeding and data centers - The company is in discussions with multiple parties regarding data centers and expects to finalize contracts with two parties, Atlas and Sabey, by the end of Q2 2025 [40][43][44] Question: EPS guidance for 2025 - Management expects to stay within the 4% to 6% EPS range long-term but acknowledges variability in achieving this target [50] Question: Changes in electric average customer counts - The change in customer counts was due to a new system for counting street lighting districts, with overall customer growth remaining around 1.5% [54][55] Question: Long-term capacity planning - The company is considering natural gas or nuclear as potential replacements for Colstrip, depending on regulatory timelines [64][66] Question: SB301 and approval processes - The 90-day cost prudency review is deemed appropriate, with no overlapping of approval processes expected [68]

BrightSpire Capital (BRSP) Q1 2025 Earnings Call April 30, 2025 10:00 AM ET Company Participants David Palamé - Executive VP, General Counsel & SecretaryMichael Mazzei - CEO & Board MemberAndrew Witt - President & COOFrank Saracino - Executive VP, CFO & TreasurerSteve Delaney - Director of MortgageJason Weaver - Managing Director - Equity ResearchJohn Nickodemus - Vice President, Equity ResearchRandy Binner - Managing DirectorGaurav Mehta - Managing Director Operator Good day, and welcome to the BrightSpire ...